SARC's Podcast SARCTalk Continues to Inform and Inspire the Sarcoma Community
SARCTalk brings together leading oncologists, researchers, patient advocates, and survivors to discuss key topics ranging from groundbreaking clinical trials and emerging therapies to the personal journeys of those affected by sarcoma. 'SARCTalk plays a vital role in bridging the gap between scientific research and patient outcomes by fostering open dialogue and sharing sarcoma experts' knowledge with both lay and professional audiences,' said Scott Okuno MD, originator and host of SARCTalk and Chief Medical Officer of SARC. Dr. Okuno is a medical oncologist at Mayo Clinic.
Each season of SARCTalk has expanded its impact, covering diverse topics such as:
Cutting-edge research and clinical trials
Patient and survivor stories of resilience
Advances in precision medicine and immunotherapy
The role of advocacy in driving change
Expert guidance on treatment options and supportive care
Mentorship and career development
'We created SARCTalk to bring the latest advancements in sarcoma research directly to those who need it most,' said Steven Young, President and CEO at SARC. 'The response has been incredible, and it's clear that this platform is helping to educate, empower, and connect the sarcoma community like never before.'
Listeners can tune in to SARCTalk (for audio only) on Spotify & Apple Podcast and (plus video) YouTube & SARC's website https://sarctrials.org/resources/sarc-podcast. Stay connected with SARC for the latest sarcoma research and advocacy updates at https://sarctrials.org/.
About SARC
SARC (Sarcoma Alliance for Research Through Collaboration) is a US-based, non-profit public charity sarcoma research consortium solely dedicated to fostering progress in the prevention and treatment of sarcoma to improve patient outcomes and ultimately find a cure.
SARC was formed in 2003 by the sarcoma research community to bring together the best cancer centers in the world supported by centralized infrastructure for the conduct of multi-institutional collaborative sarcoma research.
SARC has successfully established itself as a leader in providing a unified platform for sarcoma experts to collaborate and fast-track more dozens of Phase I-III clinical trials (with SARC as regulatory sponsor) across close to 100 medical centers with specialized sarcoma programs in the United States and globally.
What Is Sarcoma?
Sarcomas are cancers of the bony skeleton (the skull, vertebrae, ribs, and extremities), and the so-called soft tissues, including muscle and fat. Sarcomas are disproportionately common in children and young adults but occur at all ages. There are many different types of sarcomas, leading to diagnostic and therapeutic challenges. SARC and our collaborators are working to advance the science and treatment of sarcomas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe
LEATHERHEAD, England, July 3, 2025 /PRNewswire/ — MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has received its CE mark, confirming compliance with European safety and performance standards. This important milestone expands access to hip resurfacing, enabling wider availability across the UK, Europe and internationally where CE marking supports market access. 'This is more than a regulatory milestone. It represents two decades of focused effort to improve hip resurfacing through an advanced material,' said Mike Tuke, Founder of MatOrtho. 'That became a possibility with BIOLOX® delta and cooperation with CeramTec A.G. which led in stages to ReCerf – an all-ceramic resurfacing implant that is already delivering excellent results. We're proud to make this more widely available to specialist hip resurfacing surgeons, and patients who want to stay active.' ReCerf is the world's first commercially available ceramic HRA, first approved by Australia's Therapeutic Goods Administration in November 2024. Since its initial use in 2018, over 1,600 patients have received the device. Patient-reported outcomes are highly positive, and the revision rate remains very low up to six years. Made from BIOLOX® delta ceramic, ReCerf eliminates concerns historically associated with metal-on-metal bearings and preserves more of the patient's natural bone. For surgeons, it offers a familiar procedure underpinned by improved materials, and is supported by a company long recognised as the home of modern hip resurfacing. ReCerf's availability under CE marking is matched by a strong commitment to responsible adoption. MatOrtho supports structured education, careful patient selection, and ongoing clinical monitoring. A peer-led surgeon training programme is already in place to ensure safe and effective use. This achievement strengthens MatOrtho's strategic growth and reaffirms its leadership in pioneering orthopaedic solutions designed to restore normal joint function and support high level activity. For more information visit: About MatOrtho: MatOrtho (formerly Finsbury Orthopaedics) is a global leader in orthopaedic invention and innovation, committed to advancing joint replacement technologies that improve patient outcomes and set new clinical standards. Website: Photo – – View original content:
The Sun
8 hours ago
- The Sun
BeauEver Secures NZ Prime Minister's Support in Historic China Summit to Accelerate Global Skincare Expansion
SHANGHAI, CHINA - Media OutReach Newswire - 2 July 2025 - At the 2025 China–New Zealand Trade Innovation Summit, New Zealand Prime Minister, the Right Hon. Christopher Luxon, witnessed the official signing of a strategic partnership between high-end anti-aging brand BeauEver and biotechnology leader The Beauty Lab Collective (TBLC). This milestone partnership deepens economic cooperation between New Zealand and China while promoting the global development of responsible, science-driven skincare innovation. 'This partnership reflects the strength of the NZ–China relationship and our commitment to global innovation,' said Prime Minister Luxon. 'BeauEver represents the best of New Zealand — science, sustainability, and international vision.' The agreement includes the launch of a New Zealand-based Active Ingredient Innovation Center, dedicated to researching marine and botanical compounds native to New Zealand's pristine ecosystems. Through TBLC's certified cruelty-free infrastructure and intelligent manufacturing, BeauEver aims to enhance its capacity to meet the evolving needs of consumers in China and across Southeast Asia. 'Our mission is to become a globally trusted name in cellular anti-aging — where nature meets science, and skincare becomes a meaningful, restorative ritual. This partnership helps us share that philosophy with more women around the world.' said Liam Corkery, General Manager of BeauEver New Zealand. BeauEver's innovation is grounded in more than 40 years of research into bioactive ingredients and cell-level rejuvenation. With dual R&D centers in Switzerland and New Zealand, the brand focuses on holistic skin renewal by supporting mitochondrial vitality, collagen stimulation, and skin-barrier reinforcement. At the heart of its product line is the BeauEver Cell-Reviving Firming and Rejuvenating Essence — a lightweight, high-efficacy formula designed to support skin's natural renewal process. Powered by bio-fermented actives, transdermal collagen delivery, and barrier-enhancing peptides, the essence helps improve the appearance of firmness, radiance, and resilience over time. It embodies BeauEver's brand philosophy: to awaken the body's natural energy and deliver visible results with integrity, science, and care. With a reported 300% year-on-year growth in 2024 in China market, BeauEver is rapidly expanding its global footprint in the premium skincare space — particularly among dermatology clinics, spa professionals, and wellness institutions across Asia-Pacific.
Sinar Daily
9 hours ago
- Sinar Daily
Director of Indonesia hospital in Gaza and family killed in Israeli airstrike
The Medical Emergency Rescue Committee (MER‑C), a Jakarta-based non-governmental organisation that operates the hospital, confirmed the deaths in a statement citing information from its local team in Gaza. 03 Jul 2025 01:30pm This picture shows the rubble of a residential house in Deir el-Balah in the central Gaza Strip on July 1, 2025. (Photo by Eyad BABA / AFP) JAKARTA - The director of the Indonesia Hospital in Gaza, Dr Marwan Al-Sultan, was killed along with members of his family in an Israeli airstrike on their home in Tal al-Hawa, southwest Gaza City, on Wednesday, according to an Indonesian humanitarian organisation. The Medical Emergency Rescue Committee (MER‑C), a Jakarta-based non-governmental organisation that operates the hospital, confirmed the deaths in a statement citing information from its local team in Gaza. This picture shows the rubble of a residential house in Deir el-Balah in the central Gaza Strip on July 1, 2025. (Photo by Eyad BABA / AFP) "With deep sorrow, we announce the death of Dr Marwan and members of his family, following a direct airstrike on their residence,' a local MER‑C volunteer said. At least nine Palestinians were killed and several others injured in the attack, the organisation said. Dr Marwan, a Palestinian, was described as a "highly dedicated medical professional' who had served the people of Gaza for many years, particularly during repeated crises and armed conflicts. "His passing is a profound loss, not only to his colleagues but also to his patients and the wider Gaza community who knew him. May he and his family be granted the best place in the hereafter,' MER-C added. Meanwhile, the Palestinian Health Ministry in Gaza condemned the attack, calling it a "heinous crime' against medical personnel. "Every crime against medical and humanitarian personnel confirms the bloody methodology and the premeditated insistence on directly and deliberately targeting them,' the ministry stated in a statement. The Indonesian government also expressed its condolences and strong condemnation. "Indonesia expresses its deep condolences over the passing of Dr Marwan along with his family on July 2, and strongly condemns the Israeli attack,' the Foreign Ministry posted on X. The statement praised Dr Marwan's "service, commitment, and struggle in the name of humanity and for peace in Palestine,' and said Indonesia was continuing to closely monitor developments at the hospital. Indonesia reiterated its call for an immediate ceasefire and an end to what it described as "Israel's atrocities'. The Indonesia Hospital in northern Gaza, funded by Indonesian civil society, has provided critical trauma care since 2016, with Dr Marwan playing a central role in sustaining its operations amid ongoing conflict. - BERNAMA More Like This
